New Orleans, May 2025 – ChemT Biotechnology President and Cofounder Dr. Ling Wu participated in the International Society for Cell & Gene Therapy (ISCT) 2025 conference in New Orleans, engaging with global leaders in cell therapy and highlighting its proprietary AI-designed small molecule, Chemplify, that directly addresses T-cell senescence, a universal bottleneck in cell therapy manufacturing. Senescence — the gradual loss of T cell potency during expansion — has long limited yields and therapeutic effectiveness across both autologous and allogeneic therapies.

Designed to tackle the universal challenge of T cell senescence during expansion, Chemplify helps maintain a “young” T cell phenotype, boosts T cell yields by up to 10 times, and reduces production time by up to 50%. These performance gains aim to improve the quality of T cell products while lowering manufacturing costs, offering significant benefits for developers of CAR-T, TCR-T, and other autologous or allogeneic T cell therapies.

ChemT is also collaborating with the National Cancer Centre Singapore (NCCS) to advance next-generation cell therapies for patients.